Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial

Fig. 2

Factors associated with NAPSI 0/1 in patients receiving guselkumab. Figure shows association with NAPSI 0/1 at a) week 24 and b) week 48. Data are from a multiple logistic regression analysis and include all patients with fingernail psoriasis randomized to guselkumab (patients who achieved a PASI90 response and those who did not). All variables are at baseline, unless otherwise stated. aPASI: absolute Psoriasis Area and Severity Index; BMI: body mass index; CI: confidence interval; CRP: C-reactive protein; GUS: guselkumab; NAPSI: Nail Psoriasis Severity Index; NR: non-response (< PASI90 response at Week 28); PBO: placebo; R: response (achieving PASI90 response at Week 28)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us